journal
MENU ▼
Read by QxMD icon Read
search

Lancet Haematology

journal
https://www.readbyqxmd.com/read/28522110/high-dose-gemcitabine-busulfan-and-melphalan-for-autologous-stem-cell-transplant-in-patients-with-relapsed-or-refractory-myeloma-a-phase-2-trial-and-matched-pair-comparison-with-melphalan
#1
Yago Nieto, Benigno C Valdez, Sai R Pingali, Roland Bassett, Ruby Delgado, John Nguyen, Nina Shah, Uday Popat, Roy B Jones, Borje S Andersson, Alison Gulbis, Sairah Ahmed, Qaiser Bashir, Simrit Parmar, Krina Patel, Alan Myers, Gabriela Rondon, Robert Z Orlowski, Richard Champlin, Muzaffar Qazilbash
BACKGROUND: High-dose melphalan is of little benefit as a regimen for patients with relapsed or refractory myeloma undergoing an autologous stem-cell transplant (ASCT). The poor performance of single-agent melphalan in this setting prompted us to study a new high-dose combination of infused gemcitabine, busulfan, and melphalan. METHODS: We did a phase 2 trial at the University of Texas MD Anderson Cancer Center (Houston, TX, USA). We enrolled patients with primary refractory or relapsed myeloma who had received treatment with bortezomib, an immunomodulatory drug, or both, or who were receiving a salvage ASCT...
May 15, 2017: Lancet Haematology
https://www.readbyqxmd.com/read/28522109/gemcitabine-busulfan-and-melphalan-conditioning-for-autologous-stem-cell-transplants-in-multiple-myeloma
#2
Gösta Gahrton
No abstract text is available yet for this article.
May 15, 2017: Lancet Haematology
https://www.readbyqxmd.com/read/28476440/efficacy-and-safety-of-subcutaneous-rituximab-versus-intravenous-rituximab-for-first-line-treatment-of-follicular-lymphoma-sabrina-a-randomised-open-label-phase-3-trial
#3
Andrew Davies, Francesco Merli, Biljana Mihaljević, Santiago Mercadal, Noppadol Siritanaratkul, Philippe Solal-Céligny, Axel Boehnke, Claude Berge, Magali Genevray, Artem Zharkov, Mark Dixon, Michael Brewster, Martin Barrett, David MacDonald
BACKGROUND: Intravenous rituximab is the standard of care in B-cell non-Hodgkin lymphoma, and is administered over 1·5-6 h. A subcutaneous formulation could reduce patients' treatment burden and improve resource utilisation in health care. We aimed to show the pharmacokinetic non-inferiority of subcutaneous rituximab to intravenous rituximab in follicular lymphoma and to provide efficacy and safety data. METHODS: SABRINA is a two-stage, randomised, open-label phase 3 study at 113 centres in 30 countries...
May 2, 2017: Lancet Haematology
https://www.readbyqxmd.com/read/28457981/coagulation-factor-concentrates-and-point-of-care-coagulation-monitoring-both-might-be-essential-for-optimal-treatment-of-trauma-induced-coagulopathy
#4
Oliver Grottke, Rolf Rossaint
No abstract text is available yet for this article.
April 27, 2017: Lancet Haematology
https://www.readbyqxmd.com/read/28457980/reversal-of-trauma-induced-coagulopathy-using-first-line-coagulation-factor-concentrates-or-fresh-frozen-plasma-retic-a-single-centre-parallel-group-open-label-randomised-trial
#5
Petra Innerhofer, Dietmar Fries, Markus Mittermayr, Nicole Innerhofer, Daniel von Langen, Tobias Hell, Gottfried Gruber, Stefan Schmid, Barbara Friesenecker, Ingo H Lorenz, Mathias Ströhle, Verena Rastner, Susanne Trübsbach, Helmut Raab, Benedikt Treml, Dieter Wally, Benjamin Treichl, Agnes Mayer, Christof Kranewitter, Elgar Oswald
BACKGROUND: Effective treatment of trauma-induced coagulopathy is important; however, the optimal therapy is still not known. We aimed to compare the efficacy of first-line therapy using fresh frozen plasma (FFP) or coagulation factor concentrates (CFC) for the reversal of trauma-induced coagulopathy, the arising transfusion requirements, and consequently the development of multiple organ failure. METHODS: This single-centre, parallel-group, open-label, randomised trial was done at the Level 1 Trauma Center in Innsbruck Medical University Hospital (Innsbruck, Austria)...
April 27, 2017: Lancet Haematology
https://www.readbyqxmd.com/read/28411122/the-lure-and-pitfalls-of-administrative-health-registers
#6
Søren Paaske Johnsen
No abstract text is available yet for this article.
April 11, 2017: Lancet Haematology
https://www.readbyqxmd.com/read/28389344/emergency-transfusion-of-patients-with-unknown-blood-type-with-blood-group-o-rhesus-d-positive-red-blood-cell-concentrates-a-prospective-single-centre-observational-study
#7
Kathleen Selleng, Gregor Jenichen, Kathrin Denker, Sixten Selleng, Bernd Müllejans, Andreas Greinacher
BACKGROUND: Emergency patients with unknown blood type usually receive O Rhesus D negative (RhD-) red blood cell concentrates until their blood group is determined to prevent RhD+ related adverse transfusion reactions. As 85% of individuals are RhD+, this consumption of O RhD- red blood cell concentrates contributes to shortages of O RhD- red blood cell concentrates, sometimes forcing transfusion of known RhD- patients with RhD+ red blood cell concentrates. Here we report the outcome of this transfusion policy transfusing all emergency patients with unknown blood type with O RhD+ red blood cell concentrates...
April 4, 2017: Lancet Haematology
https://www.readbyqxmd.com/read/28314698/chemotherapy-free-treatment-in-non-hodgkin-lymphoma-a-steep-learning-curve
#8
Patrick M Reagan, Paul M Barr
No abstract text is available yet for this article.
March 14, 2017: Lancet Haematology
https://www.readbyqxmd.com/read/28460817/correction-to-lancet-haematol-2017-4-e183-91
#9
(no author information available yet)
No abstract text is available yet for this article.
May 2017: Lancet Haematology
https://www.readbyqxmd.com/read/28460816/correction-to-lancet-haematol-2017-4-e202-17
#10
(no author information available yet)
No abstract text is available yet for this article.
May 2017: Lancet Haematology
https://www.readbyqxmd.com/read/28460815/correction-to-lancet-haematol-2017-4-e154-55
#11
(no author information available yet)
No abstract text is available yet for this article.
May 2017: Lancet Haematology
https://www.readbyqxmd.com/read/28460814/what-should-be-the-endpoints-of-a-symptomatic-drug-and-its-control
#12
Giuseppe Leone
No abstract text is available yet for this article.
May 2017: Lancet Haematology
https://www.readbyqxmd.com/read/28460813/conservation-of-the-group-o-rhesus-d-negative-blood-supply
#13
Lynne Uhl
No abstract text is available yet for this article.
May 2017: Lancet Haematology
https://www.readbyqxmd.com/read/28460812/global-improvements-in-childhood-leukaemia-survival
#14
EDITORIAL
The Lancet Haematology
No abstract text is available yet for this article.
May 2017: Lancet Haematology
https://www.readbyqxmd.com/read/28411121/issues-raised-by-the-incidence-and-survival-of-childhood-cancers
#15
Philippe Autier
No abstract text is available yet for this article.
May 2017: Lancet Haematology
https://www.readbyqxmd.com/read/28411120/effectiveness-and-safety-of-rivaroxaban-and-warfarin-in-patients-with-unprovoked-venous-thromboembolism-a-propensity-matched-nationwide-cohort-study
#16
Torben B Larsen, Flemming Skjøth, Jette N Kjældgaard, Gregory Y H Lip, Peter B Nielsen, Mette Søgaard
BACKGROUND: Deep vein thrombosis (DVT) and pulmonary embolism are collectively known as venous thromboembolism (VTE), which is a common vascular disease and a major cause of morbidity and mortality worldwide. We compare effectiveness and safety of rivaroxaban versus warfarin in a prospective cohort of routine care patients with incident unprovoked VTE. METHODS: In this propensity-matched cohort study, we linked nationwide Danish health registries to identify all patients with a first hospital diagnosis of unprovoked VTE who were new users of rivaroxaban or warfarin...
May 2017: Lancet Haematology
https://www.readbyqxmd.com/read/28411119/worldwide-comparison-of-survival-from-childhood-leukaemia-for-1995-2009-by-subtype-age-and-sex-concord-2-a-population-based-study-of-individual-data-for-89%C3%A2-828-children-from-198-registries-in-53-countries
#17
Audrey Bonaventure, Rhea Harewood, Charles A Stiller, Gemma Gatta, Jacqueline Clavel, Daniela C Stefan, Helena Carreira, Devon Spika, Rafael Marcos-Gragera, Rafael Peris-Bonet, Marion Piñeros, Milena Sant, Claudia E Kuehni, Michael F G Murphy, Michel P Coleman, Claudia Allemani
BACKGROUND: Global inequalities in access to health care are reflected in differences in cancer survival. The CONCORD programme was designed to assess worldwide differences and trends in population-based cancer survival. In this population-based study, we aimed to estimate survival inequalities globally for several subtypes of childhood leukaemia. METHODS: Cancer registries participating in CONCORD were asked to submit tumour registrations for all children aged 0-14 years who were diagnosed with leukaemia between Jan 1, 1995, and Dec 31, 2009, and followed up until Dec 31, 2009...
May 2017: Lancet Haematology
https://www.readbyqxmd.com/read/28336242/pacritinib-versus-best-available-therapy-for-the-treatment-of-myelofibrosis-irrespective-of-baseline-cytopenias-persist-1-an-international-randomised-phase-3-trial
#18
Ruben A Mesa, Alessandro M Vannucchi, Adam Mead, Miklos Egyed, Anita Szoke, Aleksandr Suvorov, Janos Jakucs, Andrew Perkins, Ritam Prasad, Jiri Mayer, Judit Demeter, Peter Ganly, Jack W Singer, Huafeng Zhou, James P Dean, Peter A Te Boekhorst, Jyoti Nangalia, Jean-Jacques Kiladjian, Claire N Harrison
BACKGROUND: Available therapies for myelofibrosis can exacerbate cytopenias and are not indicated for patients with severe thrombocytopenia. Pacritinib, which inhibits both JAK2 and FLT3, induced spleen responses with limited myelosuppression in phase 1/2 trials. We aimed to assess the efficacy and safety of pacritinib versus best available therapy in patients with myelofibrosis irrespective of baseline cytopenias. METHODS: This international, multicentre, randomised, phase 3 trial (PERSIST-1) was done at 67 sites in 12 countries...
May 2017: Lancet Haematology
https://www.readbyqxmd.com/read/28363340/anticoagulant-therapy-for-symptomatic-calf-deep-vein-thrombosis-authors-reply
#19
LETTER
Marc Righini, Jean-Philippe Galanaud, Grégoire Le Gal
No abstract text is available yet for this article.
April 2017: Lancet Haematology
https://www.readbyqxmd.com/read/28363339/anticoagulant-therapy-for-symptomatic-calf-deep-vein-thrombosis
#20
LETTER
Michelangelo Sartori, Benilde Cosmi
No abstract text is available yet for this article.
April 2017: Lancet Haematology
journal
journal
49595
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"